Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
Tina J. Hieken(Mayo Clinic), Matthew S. Block(Mayo Clinic in Arizona)
Cited by 25
Related Papers
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis
|Nature Medicine|1995|886
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
|Clinical Cancer Research|2018|97
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer
|Clinical Cancer Research|2017|74